ReShape Lifesciences (RSLS) entered into an exclusive agreement to import and distribute Motion Informatics' AI-powered neuromuscular rehabilitation devices in the US.
Haifa, Israel-based Motion Informatics' flagship product, the Stimel-03, has received clearance from the US Food and Drug Administration, ReShape Lifesciences said Wednesday in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.